Want to see LYEL full AI Analyst Report?
Lyell Immunopharma (LYEL) Income Statement
Lyell Immunopharma Income Statement
Last quarter (Q2 2026), Lyell Immunopharma's total revenue was $4.00K, a decrease of 50.00% from the same quarter last year. In Q2, Lyell Immunopharma's net income was $-44.76M. See Lyell Immunopharma’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 36.00K | $ 61.00K | $ 130.00K | $ 84.68M | $ 10.65M | |
| $ -11.50M | $ 61.00K | $ 130.00K | $ 84.68M | $ 10.65M | |
| $ 192.27M | $ 358.82M | $ 247.14M | $ 271.74M | $ 225.43M | |
| Depreciation and Amortization | $ 11.54M | $ 19.63M | $ 20.25M | $ 18.02M | $ 13.62M |
| $ -262.91M | $ -200.64M | $ -214.38M | $ -165.10M | $ -236.59M | |
| $ -203.77M | $ -358.75M | $ -247.01M | $ -187.06M | $ -214.78M | |
| $ -70.67M | $ 15.76M | $ 12.38M | $ 3.94M | $ -35.44M | |
| $ -274.45M | $ -342.99M | $ -234.63M | $ -183.12M | $ -250.22M | |
| $ -274.45M | $ -342.99M | $ -234.63M | $ -183.12M | $ -250.22M | |
| Per Share Metrics | |||||
| Basic EPS | $ -16.06 | $ -1.31 | $ -0.93 | $ -0.74 | $ -1.03 |
| Diluted EPS | $ -16.06 | $ -1.31 | $ -0.93 | $ -0.74 | $ -1.03 |
| Weighted Average Shares Outstanding | 17.09M | 13.07M | 12.55M | 12.35M | 12.14M |
| Weighted Average Shares Outstanding (Diluted) | 17.09M | 13.07M | 12.55M | 12.35M | 12.14M |
Currency in USD
